The drug and medical device contract clinical development services provider announced the expansion today, nearly two months after launching its startup acceleration program.
"Our expansion is driven by increasing demand for our services," Kurt Mussina, Frenova general manager told Outsourcing-Pharma.com.
"The increasing demand is driven by a) the current and projected prevalence of CKD and the burden of CKD on healthcare cost and delivery, b) the fact that many drugs on the market today were approved through a clinical development pathway that specifically excluded patients with impaired renal function," he added.
Mussina also commented that the company’s new presence in Durham will provide it with access to a pool of “talented clinical research professionals to facilitate our growth and better serve our clients.”
As Outsourcing-Pharma.com previously reported, Frenova launched its inaugural group of site businesses which comprise F1RST Up, a program designed to accelerate study status by eliminating common administrative and contacting issues.
“F1RST Up is the rapid startup component of Frenova’s site network, a highly select group of exceptionally performing renal research sites with large, diverse patient populations that are available and ready to enroll quickly to help clients get studies underway faster,” said Kurt Mussina, Frenova’s VP and general manager.
Earlier this month, Quintiles and DaVita Clinical Research also announced a strategic alliance to help optimize renal clinical trials.
According to Jeanne Hecht, SVP and global head, site & patient networks at Quintiles, such clinical studies pose a series of challenges, "from progressively complex protocol designs to an increasing demand for broad patient population participation."